2 Reasons Moderna Will Be a Top Growth Stock in 2021
For much of 2020, Moderna (NASDAQ: MRNA) has been a superb growth stock. At one point recently, Moderna was a ten-bagger before falling by more than 35%. But even after that slide, it has delivered a spectacular 483% return over the past 12 months. However, many investors now wonder if it can regain its momentum.
In many cases with emerging biotechs, institutional investors will purchase stakes after a positive late-stage clinical data release, then sell en masse after the therapeutic candidate's approval. The idea behind that strategy is that once a drug goes into commercialization, it could underperform its sales expectations. This is simply not the case for Moderna's new product, however.
In my view, now is the right time to add shares of Moderna to your portfolio for 2021. Here's why.
Source Fool.com
